Clinical and Translational Results of a Phase II, Randomized Trial of an AntiIGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

Clinical Cancer Research

Volumn 22, Issue 2, 2016, Pages 301-309

  Gradishar, William J ^a   Yardley, Denise A ^b,c   Layman, Rachel ^d   Sparano, Joseph A ^e   Chuang, Ellen ^f   Northfelt, Donald W ^g   Schwartz, Gary N ^h   Youssoufian, Hagop ⁱ   Tang, Shande ^j   Novosiadly, Ruslan ^j   Forest, Amelie ^j   Nguyen, Tuan S ^j   Cosaert, Jan ^j,l   Grebennik, Dmitri ^j,m   Haluska, Paul ^k,n  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c PLLC   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g MAYO CLINIC   (United States)

^h DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

ⁱ Clinical Research   (United States)

^j ELI LILLY AND COMPANY   (United States)

^k MAYO CLINIC CANCER CENTER   (United States)

^l Sotio   (Czech Republic)

^m KYOWA HAKKO KOGYO CO LTD   (Japan)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CIXUTUMUMAB; INSULIN RECEPTOR; INSULIN RECEPTOR A; INSULIN RECEPTOR B; MESSENGER RNA; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANTI-IGF-1R ANTIBODY A12; MONOCLONAL ANTIBODY; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BLURRED VISION; BREAST ADENOCARCINOMA; CANCER HORMONE THERAPY; CANCER TISSUE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; VERY ELDERLY; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; RECEPTOR, IGF TYPE 1; RNA, MESSENGER;

EID: 84958961569     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0588     Document Type: Article

References (45)

1. Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev 2014;40: 862-71.
2. Santen RJ, Song RX, Zhang Z, YueW, Kumar R. Adaptive hypersensitivity to estrogen: Mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 2004;10:337S-45S.
3. Song RX, Zhang Z, Chen Y, Bao Y, Santen RJ. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogenactivated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007;148:4091-101.
4. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 2005;146:4609-18.
5. Chong K, Subramanian A, Sharma A, Mokbel K. Measuring IGF-1, ER-a and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer. Anticancer Res 2011;31:23-32.
6. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, et al. Adaptive hypersensitivity to estrogen:mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005;95:155-65.
7. Zhang Y,MoerkensM, Ramaiahgari S, De Bont H, Price L, Meerman J, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res 2011;13:R52.
8. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003;63:8912-21.
9. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, et al. Insulinlike growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004;11:793-814.
10. Parisot JP, Hu XF, DeLuise M, Zalcberg JR. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 1999;79:693-700.
11. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.Cancer Res 2010;70:741-51.
12. Belfiore A, Frasca F. IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:381-406.
13. Belardi V, Gallagher EJ, Novosyadlyy R, LeRoith D. Insulin and IGFs in obesity-related breast cancer. J Mammary Gland Biol Neoplasia 2013; 18:277-89.
14. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992;52:3924-30.
15. Knudsen L, De Meyts P, Kiselyov VV. Insight into themolecular basis for the kinetic differences between the two insulin receptor isoforms. Biochem J 2011;440:397-403.
16. Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res 2012;22:108-15.
17. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623.
18. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277:39684-95.
19. Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012;72:3-12.
20. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-73.
21. Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 2007;106:39-47.
22. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 1997;109:565-71.
23. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, et al. In vivo effects of thehuman type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11:3065-74.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
25. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, v3.0. Available from: Http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
26. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Doubleblind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20:3386-95.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81.
28. Cox DR. Regression models and life-tables. J R Stat Soc Series B (Methodological) 1972;34:187-220.
29. Bland JM, Altman DG. The logrank test. BMJ 2004;328:1073.
30. RobertsonJF, FerreroJM,Bourgeois H,KenneckeH, deBoerRH, JacotW,et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: A randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 2013;14:228-35.
31. MaCX, SumanVJ, Goetz M, Haluska P, Moynihan T, Nanda R, et al.A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 2013;139:145-53.
32. Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Mol Cancer Ther 2008;7:2575-88.
33. Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, et al. An openlabel, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer 2013;49:3219-28.
34. Hartog H, Wesseling J, Boezen HM, Van Der Graaf WT. The insulin-like growth factor 1 receptor in cancer: Old focus, new future. Eur J Cancer 2007;43:1895-904.
35. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990;86:1503-10.
36. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A,Hilsenbeck SG, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008;26: 4078-85.
37. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2006; 13:593-605.
38. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 1997;109:565-71.
39. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68:10238-46.
40. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene 1999;18:2471-9.
41. Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer 2014;61:452-6.
42. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol 2012;30: 256-62.
43. Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, et al. Cixutumumab and temsirolimus for patients with bone and softtissue sarcoma: A multicentre, open-label, phase 2 trial. Lancet Oncol 2013; 14:371-82.
44. Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial. Lancet Oncol 2014;15: 191-200.
45. Harris AL, Dowsett M, Smith IE, Jeffcoate S. Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. Br J Cancer 1983;48:585-94.